Cargando…
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
INTRODUCTION: Low bone mineral density (BMD) and osteoporosis are prevalent in HIV-infected patients and were associated with HIV infection and tenofovir-containing ART. MATERIALS AND METHODS: The GUSTA study (GUided Simplification with Tropism Assay) is a two-arm, prospective, multicenter, 1:1 rand...
Autores principales: | Bianco, Claudia, Rossetti, Barbara, Gagliardini, Roberta, Lamonica, Silvia, Fanti, Luri, Lombardi, Francesca, Cauda, Roberto, Di Giambenedetto, Simona, De Luca, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International AIDS Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225387/ https://www.ncbi.nlm.nih.gov/pubmed/25397560 http://dx.doi.org/10.7448/IAS.17.4.19816 |
Ejemplares similares
-
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014) -
Intérêt pronostique à cours et à long terme du scanner thoracique chez les patients atteints de COVID-19
por: El Wadhane, I., et al.
Publicado: (2022) -
The Efficacy, Safety, And Cost Savings Of High Dose IV Diuretics For Heart Failure Patients In An Outpatient Setting With Limited Hospital Bed Space Due To Covid-19
por: Lau, Sirimas, et al.
Publicado: (2023) -
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
por: Rossetti, Barbara, et al.
Publicado: (2017) -
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
por: Rossetti, Barbara, et al.
Publicado: (2019)